Skip to main content
. 2024 Jan 24;16(1):253–263. doi: 10.21037/jtd-23-1092

Table 3. irTDs in patients receiving ICIs therapy.

ICI agent All (n=42) Hypothyroidism (n=21) Hyperthyroidism (n=7) DH (n=14)
All Overt All Overt
Pembrolizumab 18 8 6 5 3 5
Sintilimab 12 7 4 1 1 4
Atezolizumab 7 3 2 1 1 3
Camrelizumab 5 3 1 0 0 2

irTD, immune-related thyroid dysfunction; ICI, immune checkpoint inhibitor; DH, destructive thyroiditis.